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Abstract
Background—Early mortality in people initiating antiretroviral treatment (ART) in Africa 
remains high. Empiric TB treatment strategies aim to reduce early mortality by initiating TB 
treatment in individuals without clinical suspicion of TB who are at high-risk of death from 
undiagnosed TB.
Methods—Using data from 16,913 individuals starting ART under programmatic conditions, we 
simulated the impact of three empiric treatment strategies on mortality and incident TB: two 
randomized clinical trials (REMEMBER and PrOMPT) and a pragmatic approach. The main 
analysis assumed that 50% of early deaths and 100% of incident TB is averted in those eligible 
and ignored outcomes in those lost to follow up.
Results—The increase in individuals eligible for TB treatment under empirical TB treatment 
strategies ranged from 4.4% to 31.4% as compared to those started on clinical or 
mycobacteriological grounds. The proportion of deaths averted by empiric treatment strategies 
ranged from 5.5% to 25.4%. The proportion of incident TB cases averted ranged from 10.9% to 
57.3%. The proportion receiving any TB treatment during the first six months of ART increased 
from the observed 24.0% to an estimated 27.5%, 40.4% and 51.3% under the PrOMPT, 
REMEMBER and pragmatic approach, respectively.
Conclusion—The impact of empiric TB treatment strategies depends greatly on the eligibility 
criteria chosen. The additional strain placed on TB treatment facilities and the relatively limited 
impact of some empirical TB strategies raise the question whether the benefits will outweigh the 
risks at population level.
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INTRODUCTION
Mortality in people initiating combination antiretroviral treatment (cART) in sub-Saharan 
Africa remains high, especially in the first months of cART1. Postmortem studies in Africa 
showed that TB is the cause of death in 32–45% of HIV-infected individuals in the pre-ART 
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era and 42–87% in the cART era2–4, with the majority of cases not diagnosed before death 
or diagnosed too late to prevent death due to the poor sensitivity of smear microscopy and 
lack of symptoms suggestive of TB in up to 25% of individuals with culture-positive TB.5, 6
Empirical TB treatment strategies to reduce early mortality are premised on the hypothesis 
that a subset of people living with HIV is at high risk of undiagnosed TB such that the 
benefit of empirical TB treatment outweighs the risks7. It is important to note that, where 
empirical or clinical TB treatment refers to TB treatment initiation upon clinical suspicion, 
empirical TB treatment strategies start TB treatment in high-risk individuals without clinical 
suspicion of TB. Two randomized controlled trials (RCTs) and one cluster-randomized trial 
of empirical TB treatment strategies have been registered.8–10
The aim of this simulation study is to predict the population and health systems impact of 
empirical TB treatment strategies in an ART clinic population.
METHODS
Study site and clinical data
The Themba Lethu Clinic in Johannesburg, South Africa, is a public adult HIV clinic. Since 
2004, over 21,000 people have initiated cART at the clinic11. Clients receive care according 
to South African Guidelines. TB symptom screening is performed at all visits by asking 
patients about prolonged (> 2 weeks) cough or fever, night sweats, weight loss. During the 
study period, smear microscopy was the initial diagnostic, in some complemented by chest 
X-ray, culture, histopathology, or a clinical decision to prescribe TB treatment. The 
proportion of individuals started on treatment without bacteriological confirmation is about 
40%.12, 13
Empirical TB treatment strategies
We identified the key characteristics of the REMEMBER (Reducing Early Mortality and 
Early Morbidity by Empiric Tuberculosis Treatment Regimens)8 and PrOMPT (Prevention 
of Early Mortality by Presumptive Tuberculosis Treatment)9 trials, and a pragmatic strategy 
suggested by Lawn.7 Key eligibility differences between strategies relate to the level of 
immunosuppression (CD4 count <50 cells/mm3 for REMEMBER and PrOMPT; < 100 
cells/mm3 for the pragmatic strategy) and body mass index (BMI <18 for PrOMPT, any 
BMI for REMEMBER and pragmatic strategy). All strategies limit eligibility to those not 
diagnosed (bacteriologically or clinically) with active TB, those without a TB treatment 
history (to avoid first line TB treatment in people at high risk of drug-resistant TB), and 
individuals without known liver disease (to reduce the risk of hepatotoxicity). In addition, 
each strategy has unique inclusion and exclusion criteria (Table 1).
For simulation of the REMEMBER trial, we made three modifications; (1) limit to 
individuals age ≥ 18 years, (2) not exclude individuals in contact with MDR-TB as this 
information is not routinely collected, (3) exclude individuals with documented baseline 
peripheral neuropathy assuming that only grade 214 or higher is routinely recorded. 
Modifications to the eligibility criteria for simulation of the PrOMPT trial were: (1) 
operationalize “no breastfeeding” as no recorded pregnancy in last 12 months, (2) assume 
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that absence of documentation of cryptococcal disease, Kaposi sarcoma, lymphoma, or 
toxoplasmosis indicates absence of disease, and (3) pragmatically assume absence of danger 
signs in clients initiating cART at an ambulatory clinic. To simulate the impact of the 
pragmatic approach, we selected the cut-off of CD4<100 cells/mm3, defined liver disease as 
documented liver function test (ALT) ≥ 2.5 times upper normal limit, and excluded pregnant 
women (in line with the other strategies).
Assumptions and sensitivity analyses
We applied two key assumptions for the main analysis. First, all individuals receiving 
empiric TB treatment strategy are adherent to TB treatment such that 100% of incident TB is 
prevented. Second, 50% of early deaths (first 6 months of cART) are preventable by 
empirical TB treatment strategies.2–4 In sensitivity analyses, we explored assumptions that 
30% and 70% of early deaths are preventable by empirical TB treatment strategies.
In these simulations, we ignored potential deaths and incident TB in individuals lost to 
follow up. In a “best-case scenario” sensitivity analysis, we assumed that empirical TB 
treatment strategies prevent 50% of deaths in those lost to follow up (LTFU) under standard 
of care (SOC) and 100% of incident TB as people lost to HIV care may still continue TB 
treatment at their primary care clinic. We based the risk of death among people LTFU on a 
study performed at the same clinic, which observed the following 6-month risk of death 
among those LTFU: 33.0% if CD4 0 to 50 cells/mm3, 6.4% if CD4 count 51 to 100 cells/
mm3, and 8.6% if CD4 count 101 and 200 cells/mm3, and 24% among those with missing 
CD4 count15. The 6-month risk of incident TB among those LTFU was assumed to be 10%.
Simulation of population and health systems impact of empirical TB treatment strategies
Using data on all adults initiating cART at TLC between 1 April 2004 and 30 September 
2011, we first estimated the proportion of individuals starting cART eligible for empirical 
TB treatment strategies according to the strategy-specific inclusion and exclusion criteria. 
We then compared the proportion of deaths prevented (primary outcome of the RCTs) and 
proportion of incident TB cases prevented (secondary outcome of RCTs) by each empiric 
TB treatment strategy to what was observed under SOC. Next, we estimated the number of 
clients receiving any TB treatment during the first 6 months of cART, including prevalent 
TB cases (individuals on TB treatment at time of cART initiation), incident TB cases in the 
first 6 months of cART, and cases started on TB treatment under empiric TB treatment 
strategies. Finally, we calculated the number of people needed to treat (NNT) to prevent one 
case of incident TB or one death in the first 6 months of cART for each empiric TB 
treatment strategy.
Ethics statement
The study was approved by the Institutional Review Boards of the University of the 
Witwatersrand, South Africa, and University of North Carolina, USA. Patients gave written 
informed consent for use of routine data for research purposes.
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Between 1 April 2004 and 30 September 2011, 16,913 individuals initiated cART, of which 
2,856 (17%) received TB treatment at cART initiation (prevalent TB) (Table 2). The 
majority (62%) were women, median age was 36 (interquartile range [IQR] 31, 43), 52% 
had a CD4 count ≤100 cells/mm3 and median BMI was 21.6 (IQR 19.1, 24.9). In total, 1019 
deaths were recorded in the first 6 months, corresponding to 6.0% of those initiating cART. 
The 6-month risk of death decreased with increasing CD4 count: 11.3% if CD4 count 0 to 
50 cells/mm3, 5.7% if CD4 count 51 to 100, and 3.0% if CD4 count 101 to 200. Among the 
14,057 individuals not receiving TB treatment at cART initiation, 1194 cases of incident TB 
were recorded, corresponding to an 8.5% 6-month risk. The risk of incident TB decreased 
with increasing CD4 count: 13.8% if CD4 count 0 to 50 cells/mm3, 9.6% if CD4 count 51 to 
100, and 5.3% if CD4 count 101 to 200. Overall, 94.7% were retained in care during the first 
6 months of cART, 95.2% of those with and 94.6% of those without prevalent TB at cART 
initiation.
Impact of empirical TB treatment strategies
Of the 16,913 individuals initiating cART, 5311 (31.4%) were eligible for empirical TB 
treatment when implementing the pragmatic strategy, 3205 (19.0%) according to the 
REMEMBER strategy, and 736 (4.4%) when using the PrOMPT strategy (Table 3).
Under SOC, 1019 deaths were recorded in the first 6 months of cART: 198 in those with and 
821 among those without prevalent TB at start cART. Of these 1019 deaths, 518 (50.8%) 
occurred in those eligible for empirical TB treatment under the pragmatic strategy, 346 
(34.0%) in those eligible for REMEMBER and 112 (11.8%) in those eligible for PrOMPT. 
Under the assumption that 50% of early deaths in those eligible are preventable by strategy-
based empiric TB treatment, the proportion of all deaths observed among the 16,913 
individuals initiating cART that are averted would be 25.4% for the pragmatic strategy, 
17.0% for REMEMBER, and 5.5% for PrOMPT (figure 1). Consequently, 74.6% (n=760) of 
all 1019 deaths observed under SOC would still occur under the pragmatic strategy, 83.0% 
(n=846) under REMEMBER, and 94.5% (n=963) under PrOMPT. The proportion of deaths 
averted under the alternative assumption that 30% of early mortality can be prevented by 
empiric TB treatment strategies would be 15.3% for the pragmatic strategy, 10.2% for 
REMEMBER, and 3.3% for PrOMPT. When 70% of early mortality can be prevented by 
strategy-based empiric TB treatment, 35.6% of early deaths would be averted by the 
pragmatic strategy, 23.8% by REMEMBER, and 7.7% by PrOMPT.
Under SOC, 1194 incident TB cases were recorded in the first 6 months of cART among the 
14,057 judged free of TB at start of cART (table 3), of which 684 (57.3%) occurred in those 
eligible for empirical TB treatment under the pragmatic strategy, 431 (36.1%) eligible for 
REMEMBER and 130 (10.9%) eligible for PrOMPT. Based on the assumption that 100% of 
all incident TB cases are prevented, the proportion of the 1194 incident TB cases recorded 
under SOC averted would be 57.3% for the pragmatic strategy, 36.1% for REMEMBER, 
10.9% for PrOMPT strategy (Figure 2). Consequently, 42.7% (n=510) of all 1194 incident 
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TB cases observed under SOC would still occur under the pragmatic strategy, 63.9% 
(n=763) under REMEMBER, and 89.1% (n=1064) under PrOMPT.
The proportion of clients receiving any TB treatment during the first 6 months of cART was 
lowest for SOC (24.0%), increased to 27.5% for PrOMPT, 40.4% for REMEMBER, and 
51.3% for the pragmatic strategy (Figure 1).
For every 100 people started on strategy-based empiric treatment according to the pragmatic, 
REMEMBER or PrOMPT strategy, an estimated 4.9, 5.4 and 7.6, deaths would be averted, 
corresponding to a NNT of 20.5, 18.5 and 13.1 to avoid one death (table 3). For every 100 
people started on strategy-based empiric treatment according to the pragmatic, 
REMEMBER or PrOMPT strategy, an estimated 12.9, 13.4, and 17.7 cases of incident TB 
would be averted, corresponding to a NNT of 7.8, 7.4 and 5.7 to avoid one case of incident 
TB.
In sensitivity analyses the proportion of deaths averted and NNT to prevent one death were 
highly sensitive to the alternative assumptions of effectiveness of the empirical TB treatment 
strategies (Table 2).
Among the 895 individuals LTFU, an estimated 215 deaths and 76 cases of incident TB 
occurred. Extending effectiveness of empiric TB treatment to individuals lost to cART under 
SOC slightly reduced the NNT to prevent one death (16.6, 15.2 and 11.4 for pragmatic, 
REMEMBER and PrOMPT, respectively) whereas the NNT to prevent one case of incident 
TB remained almost identical (7.4, 7.1 and 5.5 for pragmatic, REMEMBER and PrOMPT, 
respectively).
DISCUSSION
The high burden of TB and HIV in sub-Saharan Africa demands innovative interventions. 
Empirical TB treatment strategies aim to start TB treatment without diagnostic delay in 
people initiating cART who are at high risk of dying from undiagnosed TB. While awaiting 
results of RCTs, we simulated the population level effect of such strategies using data from a 
large cohort of individuals starting cART under programmatic conditions.
Our results demonstrate that eligibility criteria greatly determine the impact of empirical TB 
treatment strategies at population level, with the proportion of deaths averted ranging from 
6% to 25%, and the proportion of incident TB cases averted ranging from 11% to 57%. 
Different strategies also have variable health care system effects, with the proportion of ART 
clinic clients receiving any TB treatment during the first six months of ART being similar to 
more than doubling compared to the standard of care.
The proportion of deaths averted by empirical treatment strategies will remain unknown 
until the publication of RCT results. Enrollment in the REMEMBER trial was completed in 
May 2014. The PrOMPT trial was prematurely closed due to insufficient enrolment, in line 
with our results that only 4.4% of people initiating ART are eligible for this strategy. We 
therefore performed a sensitivity analysis exploring plausible effectiveness estimates. As 
expected, the proportion of deaths averted increases and number needed to treat decreases 
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with increased effectiveness of empiric TB treatment strategies. However, even if 70% of 
early deaths in those eligible can be averted, 64 to 92% of all deaths still occur and all 
strategies result in high numbers of people placed on “unnecessary” TB treatment as most 
individuals would not have died or developed incident TB under standard of care.
We simulated a “best case scenario” of empirical treatment strategies, with 100% of incident 
TB prevented. Our assessment of effects on the health care system was limited to the single 
measure of the number of people receiving TB treatment. Available data did not allow 
simulating the risk of other potential adverse effect such as increased rates of drug toxicity, 
adverse effects on adherence due to high pill burden, failure to diagnose other infections, and 
delay in cART initiation when first starting TB treatment, factors that could result in less 
favorable outcomes of empirical TB treatment strategies. We also did not explore potential 
operational challenges, effects on the quality of care for HIV-negative TB patients, or impact 
of isoniazid preventive therapy. We could not simulate the rapidly changing landscape of TB 
diagnostics. The Xpert MTB/RIF assay on a sputum sample can detect all sputum smear-
positive TB, about 70% of sputum smear-negative TB, rifampicin resistance, and when used 
on a blood sample, about 20% of blood-culture positive cases16, 17. The point-of-care urine 
Determine TB-LAM, which is not yet endorsed by the WHO, has high sensitivity in those 
with low CD4 count18. Implementation of Xpert MTB/RIF, Determine TB-LAM and future 
novel TB diagnostics have the potential to reduce the impact of empiric TB treatment 
strategies. A cluster-randomized trial, TB Fast Track10, which uses low BMI and anemia as 
criteria for empiric TB treatment in cART-naïve individuals will be the first “second 
generation empirical treatment strategy”, evaluating the use of empiric TB treatment in the 
setting where Determine TB-LAM is available for same-day decision-making and Xpert for 
assessment of sputum at centralized laboratories.
In conclusion, the important advances in rapid diagnostics, the strain empirical TB treatment 
strategies is likely to place on already overburdened health centers, and the relatively limited 
impact of some empirical TB strategies on the total mortality and TB incidence at an ART 
clinic population level raise the question whether the benefits of empirical TB treatment 
strategies will outweigh its risks at population level. If the RCTs demonstrate high efficacy, 
then Departments of Health will need to carefully consider inclusion and exclusion criteria 
in order to maximize risk reduction at individual level, limit the effects of potential 
unnecessary exposure to TB drugs in a substantial proportion of the ART clinic population, 
and limit the negative impact an empirical treatment strategy may have on already 
overburdened TB treatment services.
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Number people receiving any TB treatment (for prevalent TB, incident TB or initiation per 
empirical treatment strategy) experiencing death, and developing incident TB in the first six 
months of cART, observed under standard of care (SOC) and predicted for three empiric TB 
treatment strategies (pragmatic, REMEMBER, PrOMPT)
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Proportion of deaths and incident TB cases occurring under standard of care (SOC) in the 
first 6 months of antiretroviral treatment that are averted by implementation of three 
empirical TB treatment strategies.
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Table 1
Inclusion and exclusion criteria for three empirical TB treatment strategies
REMEMBER8 PrOMPT9 Lawn et al.7
INCLUSION CRITERIA
  Age ≥ 13 years ≥ 18 years
  CD4+ cell count < 50 < 50 < 100 or < 50*
  Body mass index <18
EXCLUSION CRITERIA
  Diagnosis of active TB ✓ ✓ ✓
  History of TB treatment Within 96 weeks Ever Ever
  IPT for >30 days in last 48 weeks ✓ ✓
  Exposure to MDR TB ✓ ✓
  Renal insufficiency Creat. clearance
<30 mL/min
  Abnormal liver function > 2.5 ULN ≥ 5 ULN Known acute
liver disease
  Hepatitis B Surface Ag neg.
  Pregnant ✓ ✓
  Breastfeeding ✓
  Seriously ill:
  - Karnofsky performance score < 30
✓
  - Severe illness (disseminated KS; malignant
      lymphoma; toxoplasmosis)
✓
  - Danger signs (respiratory rate > 30/min, pulse
      > 120/min, temp > 39°C)
✓
  Current Grade ≥2 peripheral neuropathy ✓
  Cryptococcal meningitis (CrAG positive) ✓
*
In the simulation study, we used <100 cells/mm3
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